EP2200605A2 - Verfahren zur stabilisierung von quercetin - Google Patents
Verfahren zur stabilisierung von quercetinInfo
- Publication number
- EP2200605A2 EP2200605A2 EP08835871A EP08835871A EP2200605A2 EP 2200605 A2 EP2200605 A2 EP 2200605A2 EP 08835871 A EP08835871 A EP 08835871A EP 08835871 A EP08835871 A EP 08835871A EP 2200605 A2 EP2200605 A2 EP 2200605A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- quercetin
- vitamin
- mixture
- weight ratio
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Definitions
- antioxidants such as quercetin
- certain natural antioxidants inhibit both acute and chronic phases of free-radical induced diseases.
- some natural antioxidants exhibit synergy in their reactions with biologically relevant oxygen species, e.g., hydroxyl radicals, superoxides, oxysulfurs, sulfur dioxide, and nitrogen dioxide.
- quercetin is unstable when placed in an aqueous solution. It is therefore desirable to develop a method to increase quercetin stability.
- the present invention is based on the unexpected finding that quercetin is much more stable in a solution also containing vitamins B3 and C than in a solution containing only quercetin.
- this invention features a method for stabilizing quercetin by placing it in a solution (e.g., an aqueous solution) containing vitamin B3 and vitamin C to form a mixture and then assessing the stability of the quercetin in the mixture after an extended period of time (e.g., two weeks, two month, or one year).
- a solution e.g., an aqueous solution
- quercetin, vitamin B3, and vitamin C preferably have a weight ratio of 1 : 0.02-1 : 0.2-2.5 (e.g., 1 : 0.08 : 1).
- the concentration of quercetin can range from 20 mg/L to 10 g/L (e.g., 500 mg/L to 2 g/L).
- FIG. 1 is a chart showing stability of quercetin in two aqueous solutions containing quercetin alone (QP2-Q), and quercetin, vitamin B3, and vitamin C (QPl- QB3C), respectively, and an acidic solution containing quercetin alone (QP3-Q).
- the weight ratio between quercetin, vitamin B3, and vitamin C in the mixture can be 1 : 0.02-1 : 0.2-2.5, or any ratio in between.
- the weight ratio can be 1 : 0.04-0.5 : 0.3-2.0, 1 : 0.05-0.3 : 0.4-1.5, 1 : 0.05-0.2 : 0.5-1, and 1 : 0.1-0.2 : 0.5-1.
- Preferred ratios include 1 : 0.02 : 1, 1 : 0.04 : 1, 1 : 0.08 : 1, 1: 0.05: 1.5, and 1: 0.16: 1.
- quercetin refers to both quercetin aglycon and quercetin derivatives, e.g., quercetin-3-O-glucoside, quercetin-5-O-glucoside, quercetin-7-O- glucoside, quercetin-9-O-glucoside, quercetin-3-O-rutinoside, quercetin-3-O-[ ⁇ - rhamnosyl-(l ⁇ 2)- ⁇ -rhamnosyl-(l ⁇ 6)]- ⁇ -glucoside, quercetin-3-O-galactoside, quercetin-7-O-galactoside, quercetin-3-O-rhamnoside, and quercetin-7-O-galactoside.
- quercetin derivatives After digestion, quercetin derivatives are converted to quercetin aglycon and other active derivatives, which are absorbed in the body.
- the quantity of quercetin mentioned above refers to that of quercetin aglycon or the quercetin moiety of a quercetin derivative.
- Quercetin can be added to the composition either in a pure form or as an ingredient in a mixture (e.g., a plant extract). Examples of commercially available quercetin include QU995 (containing 99.5% quercetin) and QU985 (containing 98.5% quercetin) from Quercegen Pharma LLC (Newton, MA) and Merck KGaA (Brazil).
- vitamin B3 includes vitamin B3 in its various forms, including niacinamide, nicotinic acid, nicotinamide, inositol hexaniacinate.
- vitamin C i.e., L-ascorbic acid, D-ascorbic acid, or both
- salts e.g., sodium ascorbate
- the vitamin B3/vitamin C solution can be prepared by dissolving vitamin B3 and vitamin C in a suitable solvent, such as a pure solvent (e.g., water) or a mixture of two or more solvents. One or more quercetins are then dissolved or suspended in the vitamin B3/vitamin C solution to form a mixture.
- the mixture can be stored at a suitable temperature (e.g., 20 or 25 0 C) for an extended period of time (e.g., two weeks or two month). During the storage, the quercetin content in the mixture is determined periodically (e.g., every 24 hours or every week) via conventional methods, e.g., HPLC, to assess quercetin stability.
- a suitable solvent such as a pure solvent (e.g., water) or a mixture of two or more solvents.
- One or more quercetins are then dissolved or suspended in the vitamin B3/vitamin C solution to form a mixture.
- the mixture can be stored at a suitable temperature (e.g.
- quercetin contents in QP1-QB3C remained unchanged during the 12-day incubation period.
- the quercetin contents in QP2-Q and QP3-Q decreased by about 15% and 10% respectively during the 12-day incubation.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97671907P | 2007-10-01 | 2007-10-01 | |
PCT/US2008/076795 WO2009045735A2 (en) | 2007-10-01 | 2008-09-18 | Method for stabilizing quercetin |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2200605A2 true EP2200605A2 (de) | 2010-06-30 |
EP2200605A4 EP2200605A4 (de) | 2011-03-23 |
Family
ID=40509135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08835871A Withdrawn EP2200605A4 (de) | 2007-10-01 | 2008-09-18 | Verfahren zur stabilisierung von quercetin |
Country Status (6)
Country | Link |
---|---|
US (1) | US8202900B2 (de) |
EP (1) | EP2200605A4 (de) |
CA (1) | CA2700867C (de) |
RU (1) | RU2476217C2 (de) |
WO (1) | WO2009045735A2 (de) |
ZA (1) | ZA201002110B (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011019654A1 (en) * | 2009-08-10 | 2011-02-17 | Stokely-Van Camp, Inc. | Method for suspending a flavonoid in a beverage |
CN102766180B (zh) * | 2012-06-01 | 2015-12-02 | 贵州师范大学 | 虎耳草中两个活性单体化合物的提纯方法及其产品的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008011363A2 (en) * | 2006-07-17 | 2008-01-24 | Thomas Christian Lines | Quercetin-containing compositions |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5026721A (en) * | 1989-06-05 | 1991-06-25 | Dudrick Stanley J | Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition |
US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
DE69826253D1 (de) * | 1997-03-20 | 2004-10-21 | Coventry Group Ltd | Nährungsergänzungsmittel für kardiovasküläre gesundheit |
AT407942B (de) * | 1997-04-16 | 2001-07-25 | Husz Georg Bela | Getränk, konzentrat-kombination sowie verfahren zur herstellung eines getränkes |
US5846569A (en) * | 1997-06-20 | 1998-12-08 | Creative Labs, Inc. | Colostrum supplement |
DE19809304A1 (de) * | 1998-03-05 | 1999-09-09 | Merck Patent Gmbh | Formulierungen mit antiviraler Wirkung |
JP2002523456A (ja) | 1998-08-27 | 2002-07-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | アスコルビン酸塩−イソケルセチン組成物 |
US6277426B1 (en) * | 1998-09-18 | 2001-08-21 | Swiss Alpine Power, Inc. | Dairy product and process for making |
US6261589B1 (en) * | 1999-03-02 | 2001-07-17 | Durk Pearson | Dietary supplement nutrient soft drink composition with psychoactive effect |
CA2367387C (en) * | 1999-03-16 | 2009-06-23 | Herwig Buchholz | Composition comprising isoquercetin and ascorbic acid in a sustained release form |
US6352712B1 (en) * | 1999-04-30 | 2002-03-05 | Daniel O. Lukaczer | Dietary supplements for treating fatigue-related syndromes |
US6210701B1 (en) * | 1999-04-30 | 2001-04-03 | Healthcomm International, Inc. | Medical food for treating inflammation-related diseases |
US6299925B1 (en) * | 1999-06-29 | 2001-10-09 | Xel Herbaceuticals, Inc. | Effervescent green tea extract formulation |
US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
US6579544B1 (en) * | 2000-05-31 | 2003-06-17 | Nutriex, L.L.C. | Method for supplementing the diet |
JP2002051732A (ja) * | 2000-06-12 | 2002-02-19 | Access Business Group Llc | 食事による植物性化学物質欠乏症を矯正する組成物及び方法 |
WO2002007768A1 (en) | 2000-07-20 | 2002-01-31 | Pitman Bradford D | Dietary supplement compositions |
US6680342B2 (en) * | 2001-09-20 | 2004-01-20 | Mayo Foundation For Medical Education And Research | Methods and compositions for inhibiting the proliferation of prostate cancer cells |
US20030068391A1 (en) * | 2001-10-04 | 2003-04-10 | Harris Dennis H. | Ingestible nerve and circulatory nutritional formulation |
US6551629B1 (en) * | 2002-07-03 | 2003-04-22 | Vitacost.Com, Inc. | Cardiovascular promotion and maintenance composition |
US6821536B2 (en) * | 2002-11-22 | 2004-11-23 | Quercegen Holdings Llc | Antioxidative compositions |
US20040126461A1 (en) * | 2002-10-23 | 2004-07-01 | Lines Thomas Christian | Composition for enhancing physical performance |
US7569239B2 (en) * | 2002-11-22 | 2009-08-04 | The Frs Company | Antioxidative compositions |
US7270840B2 (en) * | 2002-11-22 | 2007-09-18 | New Sun Nutrition Llc | Antioxidative compositions |
-
2008
- 2008-09-18 RU RU2010117350/15A patent/RU2476217C2/ru not_active IP Right Cessation
- 2008-09-18 WO PCT/US2008/076795 patent/WO2009045735A2/en active Application Filing
- 2008-09-18 US US12/212,947 patent/US8202900B2/en active Active
- 2008-09-18 EP EP08835871A patent/EP2200605A4/de not_active Withdrawn
- 2008-09-18 CA CA2700867A patent/CA2700867C/en not_active Expired - Fee Related
-
2010
- 2010-03-25 ZA ZA2010/02110A patent/ZA201002110B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008011363A2 (en) * | 2006-07-17 | 2008-01-24 | Thomas Christian Lines | Quercetin-containing compositions |
Non-Patent Citations (1)
Title |
---|
See also references of WO2009045735A2 * |
Also Published As
Publication number | Publication date |
---|---|
EP2200605A4 (de) | 2011-03-23 |
RU2476217C2 (ru) | 2013-02-27 |
ZA201002110B (en) | 2010-11-24 |
US8202900B2 (en) | 2012-06-19 |
WO2009045735A3 (en) | 2009-05-28 |
US20090088580A1 (en) | 2009-04-02 |
WO2009045735A2 (en) | 2009-04-09 |
CA2700867C (en) | 2016-05-31 |
RU2010117350A (ru) | 2011-11-10 |
CA2700867A1 (en) | 2009-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012524064A5 (de) | ||
HU224964B1 (en) | Process for stabilization of naloxone and stable pharmaceutical compositions containing naloxone | |
RU2009141618A (ru) | Композиции тетрагидробиоптерина и способы его количественной оценки | |
JP6094388B2 (ja) | ペメトレキセドを含む注射用組成物 | |
HUP0301167A2 (hu) | Neurológiai rendellenességek kezelésére felhasználható szulfonil-pirrolidin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
CA2038744C (en) | Pharmaceutical composition containing slightly water-soluble drug | |
AU2008220800B2 (en) | Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms | |
US8202900B2 (en) | Method for stabilizing quercetin | |
EP1964566A1 (de) | Zubereitung mit verbesserter bioabsorption von sapropterin-hydrochlorid | |
KR20070070309A (ko) | 카테친 및 이의 유도체의 안정화된 의학 및 화장 조성물 | |
WO2003047567A8 (de) | STABILE, SAURE, WÄSSRIGE LÖSUNG ENTHALTEND α-LIPONSÄURE(-DERIVATE), VERFAHREN ZU DEREN HERSTELLUNG SOWIE IHRE VERWENDUNG | |
ES2232034T3 (es) | Combinacion de un agente bloqueante del metabolismo del acido retinoico y un tocoferol. | |
Lindan et al. | BIOCHEMICAL STUDIES ON CHLORPROMAZINE: 1. THE EFFECT OF CHLORPROMAZINE ON RESPIRATORY ACTIVITY OF ISOLATED RAT BRAIN CORTEX | |
Simpson et al. | Regulation by bicarbonate ion of intramitochondrial citrate concentration in kidney mitochondria | |
Soler et al. | Inhibition of the intracellular Ca 2+ transporter SERCA (Sarco-Endoplasmic Reticulum Ca 2+-ATPase) by the natural polyphenol epigallocatechin-3-gallate | |
JO2852B1 (en) | Anti-cancer compounds and pharmaceutical compositions | |
JP6763590B1 (ja) | ルチン組成物 | |
CA2241515A1 (en) | Aqueous composition comprising cromoglycic acid | |
NO175565B (no) | Fremgangsmåte for fremstilling av et parenteralt anvendbart, farmasöytisk preparat inneholdende et bis-indolalkaloid | |
MX2022013702A (es) | Preparacion de absorcion percutanea que comprende donepezil con estabilidad mejorada. | |
ES2411095T3 (es) | Uso de lactoles de atorvastatina como medicamentos | |
Ohnishi et al. | Inhibition in vitro linoleic acid peroxidation and haemolysis by caffeoyltryptophan | |
CA2585866A1 (en) | Stable aqueous formulation of a platin derivative | |
CN104244925B (zh) | 盐酸氢吗啡酮溶液的提高的稳定性 | |
EP3685825B1 (de) | Isoquercitrinzusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100331 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20110223 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1145646 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110927 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1145646 Country of ref document: HK |